|
|
| | Oleoyl-L-carnitine-d3 (chloride) Basic information |
| | Oleoyl-L-carnitine-d3 (chloride) Chemical Properties |
| solubility | DMF: 20 mg/ml
DMSO: 14 mg/ml
Ethanol: 20 mg/ml | | InChI | InChI=1S/C25H46ClNO3/c1-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-20-23(28)22(25(29)30)21-24(26)27(2,3)4/h12-13,22,24H,5-11,14-21H2,1-4H3/b13-12-/i21D2,22D | | InChIKey | DGLRIIZSMOWQED-JQBFNBMXSA-N | | SMILES | [O-]C(C([2H])(C(=O)CCCCCCC/C=C\CCCCCCCC)C([2H])([2H])C(Cl)[N+](C)(C)C)=O |
| | Oleoyl-L-carnitine-d3 (chloride) Usage And Synthesis |
| Description | Oleoyl-L-carnitine-d3 is intended for use as an internal standard for the quantification of oleoyl-L-carnitine (Item Nos. 26557 | 39014) by GC- or LC-MS. Oleoyl-L-carnitine is a long-chain acylcarnitine and an inhibitor of glycine transporter 2 (GlyT2; IC50 = 340 nM).1,2 It is selective for GlyT2 over GlyT1 (IC50 = >10,000 nM). Plasma levels of oleoyl-L-carnitine are increased in patients with chronic kidney disease or end-stage renal disease receiving incident hemodialysis and these are associated with cardiovascular mortality.1WARNING This product is not for human or veterinary use. | | References | [1] SAHIR KALIM. A plasma long-chain acylcarnitine predicts cardiovascular mortality in incident dialysis patients.[J]. Journal of the American Heart Association, 2013, 2 6: e000542. DOI: 10.1161/jaha.113.000542
[2] JE CARLAND. Oleoyl-l-carnitine inhibits glycine transport by GlyT2[J]. British Journal of Pharmacology, 2012, 168 4: 891-902. DOI: 10.1111/j.1476-5381.2012.02213.x |
| | Oleoyl-L-carnitine-d3 (chloride) Preparation Products And Raw materials |
|